Research ArticleClinical Studies
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia
SUSAN K. WOELICH, JAMES T. BRAUN, MARTIN W. SCHOEN, RESHMA RAMLAL, CARL E. FRETER, PAUL J. PETRUSKA and JACK M. LIONBERGER
Anticancer Research February 2017, 37 (2) 713-717;
SUSAN K. WOELICH
1SSM Saint Louis University Hospital, Saint Louis, MO, U.S.A.
JAMES T. BRAUN
1SSM Saint Louis University Hospital, Saint Louis, MO, U.S.A.
MARTIN W. SCHOEN
2Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.
RESHMA RAMLAL
2Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.
CARL E. FRETER
2Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.
PAUL J. PETRUSKA
2Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.
JACK M. LIONBERGER
2Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.
In this issue
Anticancer Research
Vol. 37, Issue 2
February 2017
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia
SUSAN K. WOELICH, JAMES T. BRAUN, MARTIN W. SCHOEN, RESHMA RAMLAL, CARL E. FRETER, PAUL J. PETRUSKA, JACK M. LIONBERGER
Anticancer Research Feb 2017, 37 (2) 713-717;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.